LPL Financial LLC Has $2.45 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

LPL Financial LLC decreased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) by 3.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 269,004 shares of the company’s stock after selling 8,765 shares during the quarter. LPL Financial LLC’s holdings in Teva Pharmaceutical Industries were worth $2,453,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of TEVA. Exor Capital LLP acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at $92,984,000. Two Sigma Investments LP increased its holdings in Teva Pharmaceutical Industries by 705.1% in the third quarter. Two Sigma Investments LP now owns 5,283,501 shares of the company’s stock valued at $42,638,000 after purchasing an additional 4,627,252 shares during the last quarter. Phoenix Holdings Ltd. increased its holdings in Teva Pharmaceutical Industries by 11.8% in the third quarter. Phoenix Holdings Ltd. now owns 20,831,080 shares of the company’s stock valued at $162,941,000 after purchasing an additional 2,201,291 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Teva Pharmaceutical Industries by 953.6% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,028,487 shares of the company’s stock valued at $19,047,000 after purchasing an additional 1,835,952 shares during the last quarter. Finally, Allianz Asset Management GmbH bought a new stake in Teva Pharmaceutical Industries in the first quarter valued at about $15,844,000. Institutional investors and hedge funds own 50.39% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 4.2 %

Shares of TEVA opened at $7.91 on Monday. The stock’s 50-day moving average price is $8.67 and its two-hundred day moving average price is $9.29. Teva Pharmaceutical Industries Limited has a 12 month low of $6.78 and a 12 month high of $11.44. The company has a current ratio of 1.10, a quick ratio of 0.71 and a debt-to-equity ratio of 2.28. The company has a market capitalization of $8.79 billion, a PE ratio of -5.49, a PEG ratio of 2.25 and a beta of 1.19.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last posted its quarterly earnings data on Wednesday, May 10th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.18). Teva Pharmaceutical Industries had a negative net margin of 10.73% and a positive return on equity of 27.58%. The firm had revenue of $3.66 billion during the quarter, compared to analysts’ expectations of $3.60 billion. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TEVA. Evercore ISI upgraded Teva Pharmaceutical Industries from an “in-line” rating to an “outperform” rating in a report on Thursday. Barclays raised their price objective on Teva Pharmaceutical Industries from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Thursday, February 9th. Finally, StockNews.com started coverage on Teva Pharmaceutical Industries in a research report on Thursday. They issued a “buy” rating for the company. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $10.75.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Sven Dethlefs sold 59,655 shares of the firm’s stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $9.89, for a total value of $589,987.95. Following the sale, the executive vice president now directly owns 165,381 shares of the company’s stock, valued at $1,635,618.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 16,491 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $9.93, for a total transaction of $163,755.63. Following the sale, the vice president now directly owns 52,449 shares of the company’s stock, valued at approximately $520,818.57. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Sven Dethlefs sold 59,655 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, February 28th. The shares were sold at an average price of $9.89, for a total value of $589,987.95. Following the sale, the executive vice president now directly owns 165,381 shares in the company, valued at $1,635,618.09. The disclosure for this sale can be found here. Insiders have sold 158,884 shares of company stock worth $1,572,797 over the last 90 days. Corporate insiders own 0.82% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

(Get Rating)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.